Roche reports setback in testing arthritis drug for COVID-19

Covid-19 Laboratory test [PHOTO CREDIT: The Scientist Magazine]
Covid-19 Laboratory test [PHOTO CREDIT: The Scientist Magazine]

Swiss pharmaceutical company Roche has announced that its arthritis drug RoActemra has not proven to be effective against COVID-19 in clinical trials.

The anti-inflammatory drug, which contains the active ingredient tocilizumab, did not improve the medical condition of hospitalised patients with pneumonia, nor did it lower their mortality.

However, Roche said on Wednesday it would continue a separate COVID-19 trial that would combine RoActemra with the antiviral drug remdesivir, which was originally developed against Ebola.

READ ALSO: COVID-19: Nigeria won’t suspend hydroxychloroquine trial — NAFDAC

Scientists around the world are testing various existing medications as potential treatments against COVID-19, including treatments against HIV and multiple sclerosis.



PT Mag Campaign AD

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.

Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.


TEXT AD: To advertise here . Call Willie +2347088095401...

BE THE FIRST TO KNOW! Subscribe to our newsletter

* indicates required


Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application